Display options
Cite
Fisher JL, Macdonald RL. The role of an alpha subtype M2-M3 His in regulating inhibition of GABAA receptor current by zinc and other divalent cations. J Neurosci. 1998;18(8):2944-53
Fisher, J. L., & Macdonald, R. L. (1998). The role of an alpha subtype M2-M3 His in regulating inhibition of GABAA receptor current by zinc and other divalent cations. The Journal of neuroscience : the official journal of the Society for Neuroscience, 18(8), 2944-53.
Fisher, J L, and Macdonald, R L. "The role of an alpha subtype M2-M3 His in regulating inhibition of GABAA receptor current by zinc and other divalent cations." The Journal of neuroscience : the official journal of the Society for Neuroscience vol. 18,8 (1998): 2944-53.
Fisher JL, Macdonald RL. The role of an alpha subtype M2-M3 His in regulating inhibition of GABAA receptor current by zinc and other divalent cations. J Neurosci. 1998 Apr 15;18(8):2944-53. PMID: 9526011; PMCID: PMC6792601.
Copy Download .nbib Format: NLM
Share it on

J Neurosci. 1998 Apr 15;18(8):2944-53.

The role of an alpha subtype M2-M3 His in regulating inhibition of GABAA receptor current by zinc and other divalent cations.

The Journal of neuroscience : the official journal of the Society for Neuroscience

J L Fisher, R L Macdonald

Affiliations

  1. Department of Neurology, University of Michigan, Ann Arbor, Michigan 48104-1687, USA.

PMID: 9526011 PMCID: PMC6792601

Abstract

Sensitivity of GABAA receptors (GABARs) to inhibition by zinc and other divalent cations is influenced by the alpha subunit subtype composition of the receptor. For example, alpha6beta3gamma2L receptors are more sensitive to inhibition by zinc than alpha1beta3gamma2L receptors. We examined the role of a His residue located in the M2-M3 extracellular domain (rat alpha6 H273) in the enhanced zinc sensitivity conferred by the alpha6 subtype. The alpha1 subtype contains an Asn (N274) residue in the equivalent location. GABA-activated whole-cell currents were obtained from L929 fibroblasts after transient transfection with expression vectors containing GABAA receptor cDNAs. Mutation of alpha1 (alpha1(N274H)) or alpha6 (alpha6(H273N)) subtypes did not alter the GABA EC50 of alphabeta3gamma2L receptors. alpha1(N274H)beta3gamma2L receptor currents were as sensitive to zinc as alpha6beta3gamma2L receptor currents, although alpha6(H273N)beta3gamma2L receptor currents had the reduced zinc sensitivity of alpha1beta3gamma2L receptor currents. We also examined the activity of other inhibitory divalent cations with varying alpha subtype dependence: nickel, cadmium, and copper. alpha6beta3gamma2L receptor currents were more sensitive to nickel, equally sensitive to cadmium, and less sensitive to copper than alpha1beta3gamma2L receptor currents. Studies with alpha1 and alpha6 chimeric subunits indicated that the structural dependencies of the activity of some of these cations were different from zinc. Compared with alpha6beta3gamma2L receptor currents, alpha6(H273N)beta3gamma2L receptor currents had reduced sensitivity to cadmium and nickel, but the sensitivity to copper was unchanged. Compared with alpha1beta3gamma2L receptor currents, alpha1(N274H)beta3gamma2L receptor currents had increased sensitivity to nickel, but the sensitivity to cadmium and copper was unchanged. These findings indicate that H273 of the alpha6 subtype plays an important role in determining the sensitivity of recombinant GABARs to the divalent cations zinc, cadmium, and nickel, but not to copper. Our results also suggest that the extracellular N-terminal domain of the alpha1 subunit contributes to a regulatory site(s) for divalent cations, conferring high sensitivity to inhibition by copper and cadmium.

References

  1. Science. 1996 Jan 19;271(5247):369-73 - PubMed
  2. J Neurophysiol. 1997 Apr;77(4):1924-38 - PubMed
  3. J Neurosci. 1992 Mar;12(3):1063-76 - PubMed
  4. Nature. 1987 Aug 13-19;328(6131):640-3 - PubMed
  5. J Neurophysiol. 1995 Nov;74(5):2012-27 - PubMed
  6. J Physiol. 1992 Feb;447:587-625 - PubMed
  7. Neuropharmacology. 1997 Jan;36(1):63-73 - PubMed
  8. J Neurosci. 1993 Apr;13(4):1418-28 - PubMed
  9. Brain Res. 1993 Apr 2;607(1-2):222-32 - PubMed
  10. Nature. 1984 Apr 19-25;308(5961):734-6 - PubMed
  11. J Neurophysiol. 1996 Oct;76(4):2536-46 - PubMed
  12. J Neurochem. 1994 Feb;62(2):602-7 - PubMed
  13. Mol Pharmacol. 1991 Nov;40(5):766-73 - PubMed
  14. Mol Pharmacol. 1996 Nov;50(5):1253-61 - PubMed
  15. J Neurosci. 1992 Nov;12(11):4151-72 - PubMed
  16. J Neurosci. 1995 Nov;15(11):7684-91 - PubMed
  17. Mol Endocrinol. 1991 Jul;5(7):921-30 - PubMed
  18. Mol Pharmacol. 1991 Mar;39(3):267-74 - PubMed
  19. J Neurosci. 1997 Jul 1;17(13):5027-37 - PubMed
  20. Mol Cell Biol. 1987 Aug;7(8):2745-52 - PubMed
  21. Mol Pharmacol. 1996 Mar;49(3):567-79 - PubMed
  22. Neurosci Lett. 1989 Aug 28;103(2):139-44 - PubMed
  23. J Neurosci. 1997 Oct 1;17(19):7532-40 - PubMed
  24. Cell Mol Neurobiol. 1994 Dec;14(6):599-621 - PubMed
  25. Synapse. 1988;2(4):412-5 - PubMed
  26. Nature. 1997 Feb 27;385(6619):820-3 - PubMed
  27. Nature. 1984 Apr 19-25;308(5961):736-8 - PubMed
  28. Mol Pharmacol. 1996 Jul;50(1):119-27 - PubMed
  29. Pharmacol Rev. 1995 Jun;47(2):181-234 - PubMed
  30. J Neurosci. 1994 Nov;14(11 Pt 2):7077-86 - PubMed
  31. Nature. 1991 Feb 7;349(6309):521-4 - PubMed
  32. Neuron. 1990 Dec;5(6):781-8 - PubMed
  33. Br J Pharmacol. 1990 Apr;99(4):643-54 - PubMed
  34. Cell Mol Neurobiol. 1994 Dec;14(6):591-7 - PubMed
  35. Mol Pharmacol. 1997 Oct;52(4):714-24 - PubMed
  36. Pflugers Arch. 1996 Oct;432(6):1080-90 - PubMed
  37. J Gen Physiol. 1996 Feb;107(2):195-205 - PubMed
  38. J Physiol. 1997 Dec 15;505 ( Pt 3):633-40 - PubMed
  39. J Neurosci. 1992 Mar;12(3):1040-62 - PubMed

Substances

MeSH terms

Publication Types

Grant support